Peringatan Keamanan

There are no data regarding overdosage with efgartigimod alfa.

Efgartigimod alfa

DB15270

biotech approved investigational

Deskripsi

Myasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction.A243759 The production of IgG autoantibodies against acetylcholine receptors (AChRs) is one of the more common pathophysiological mechanisms behind MG, and results in the destruction of these receptors and a reduction in electrical nerve impulses.A243759,A243784

Efgartigimod alfa is a first-in-classL39501 antagonist of the neonatal Fc receptor (FcRn) used in the treatment of MG.L39496 IgG antibodies, including the autoantibodies responsible for MG symptoms, can be 'recycled', a process that significantly extends their half-life by evading lysosomal degradation via binding with FcRn.L39509 By antagonizing this interaction, efgartigimod alfa prevents this recycling phase and thus decreases the half-life of IgG, effectively lowering circulating levels of IgG autoantibodies against AChRs.

Efgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021L39501 and European Commission approval on August 11, 2022.L43190 A formulation for subcutaneous use that combines efgartigimod alfa and hyaluronidase was first approved by the FDA in June 2023.L47001,L47006

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The terminal elimination half-life of efgartigimod alfa ranges from 80 to 120 hours.[L39496]
Volume Distribusi The volume of distribution of efgartigimod alfa ranges from 15 to 20 liters.[L39496]
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

As with other therapeutic proteins, efgartigimod alfa is likely metabolized to smaller peptides and amino acids via proteolytic enzymes.L39496

Rute Eliminasi

After a single intravenous dose of efgartigimod alfa 10 mg/kg in healthy subjects, less than 0.1% of the administered dose was recovered in the urine.L39496

Interaksi Obat

353 Data
Rubella virus vaccine The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Rubella virus vaccine.
Varicella zoster vaccine (live/attenuated) The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Varicella zoster vaccine (live/attenuated).
Bacillus calmette-guerin substrain tice live antigen The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Bacillus calmette-guerin substrain tice live antigen.
Bacillus calmette-guerin substrain connaught live antigen The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Bacillus calmette-guerin substrain connaught live antigen.
Yellow fever vaccine The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Yellow fever vaccine.
Anthrax vaccine The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Anthrax vaccine.
Typhoid Vaccine Live The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Typhoid Vaccine Live.
Bacillus calmette-guerin substrain danish 1331 live antigen The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Bacillus calmette-guerin substrain danish 1331 live antigen.
BCG vaccine The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with BCG vaccine.
Human adenovirus e serotype 4 strain cl-68578 antigen The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Human adenovirus e serotype 4 strain cl-68578 antigen.
Vibrio cholerae CVD 103-HgR strain live antigen The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Vibrio cholerae CVD 103-HgR strain live antigen.
Adenovirus type 7 vaccine live The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Adenovirus type 7 vaccine live.
Bacillus calmette-guerin substrain russian BCG-I live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Efgartigimod alfa.
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Efgartigimod alfa.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Efgartigimod alfa.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Efgartigimod alfa.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Efgartigimod alfa.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Efgartigimod alfa.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Efgartigimod alfa.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Efgartigimod alfa.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Efgartigimod alfa.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Efgartigimod alfa.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Efgartigimod alfa.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Efgartigimod alfa.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Efgartigimod alfa.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Efgartigimod alfa.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Efgartigimod alfa.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Efgartigimod alfa.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Efgartigimod alfa.
Trastuzumab The risk or severity of neutropenia can be increased when Trastuzumab is combined with Efgartigimod alfa.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Efgartigimod alfa.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Efgartigimod alfa.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Efgartigimod alfa.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Efgartigimod alfa.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Efgartigimod alfa.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Efgartigimod alfa.
Cyclosporine Efgartigimod alfa may increase the immunosuppressive activities of Cyclosporine.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Efgartigimod alfa.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Efgartigimod alfa.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Efgartigimod alfa.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Efgartigimod alfa.
Natalizumab The risk or severity of immunosuppression can be increased when Efgartigimod alfa is combined with Natalizumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Efgartigimod alfa.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Efgartigimod alfa.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Efgartigimod alfa.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Efgartigimod alfa.
Cladribine Efgartigimod alfa may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Efgartigimod alfa.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Efgartigimod alfa.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Efgartigimod alfa.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Efgartigimod alfa.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Efgartigimod alfa.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Efgartigimod alfa.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Efgartigimod alfa.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Efgartigimod alfa.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Efgartigimod alfa.
Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Efgartigimod alfa.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Efgartigimod alfa.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Efgartigimod alfa.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Efgartigimod alfa.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Efgartigimod alfa.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Efgartigimod alfa.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Efgartigimod alfa.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Efgartigimod alfa.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Efgartigimod alfa.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Efgartigimod alfa.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Efgartigimod alfa.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Efgartigimod alfa.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Efgartigimod alfa.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Efgartigimod alfa.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Efgartigimod alfa.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Efgartigimod alfa.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Efgartigimod alfa.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Efgartigimod alfa.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Efgartigimod alfa.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Efgartigimod alfa.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Efgartigimod alfa.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Efgartigimod alfa.
Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Efgartigimod alfa.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Efgartigimod alfa.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Efgartigimod alfa.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Efgartigimod alfa.
Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Efgartigimod alfa.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Efgartigimod alfa.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Efgartigimod alfa.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Efgartigimod alfa.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Efgartigimod alfa.
Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Efgartigimod alfa.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Efgartigimod alfa.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Efgartigimod alfa.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Efgartigimod alfa.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Efgartigimod alfa.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Efgartigimod alfa.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Efgartigimod alfa.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Efgartigimod alfa.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Efgartigimod alfa.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Efgartigimod alfa.
Mometasone The risk or severity of adverse effects can be increased when Mometasone is combined with Efgartigimod alfa.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Efgartigimod alfa.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Efgartigimod alfa.

Target Protein

IgG receptor FcRn large subunit p51 FCGRT

Referensi & Sumber

Artikel (PubMed)
  • PMID: 32644757
    Beloor Suresh A, Asuncion RMD: Myasthenia Gravis .
  • PMID: 33197578
    Lascano AM, Lalive PH: Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev. 2021 Jan;20(1):102712. doi: 10.1016/j.autrev.2020.102712. Epub 2020 Nov 13.
Link

Contoh Produk & Brand

Produk: 5 • International brands: 1
Produk
  • Vyvgart
    Injection • 20 mg/1mL • Intravenous • US • Approved
  • Vyvgart
    Injection, solution • 1000 mg • Subcutaneous • EU • Approved
  • Vyvgart
    Solution • 20 mg / mL • Intravenous • Canada • Approved
  • Vyvgart
    Injection, solution, concentrate • 20 mg/ml • Intravenous • EU • Approved
  • VYVGART Hytrulo
    Injection, solution • - • Subcutaneous • US • Approved
International Brands
  • Vyvgart — argenx BV

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul